| Bioactivity | BPH-652 is a S. aureus dehydrosqualene synthase (CrtM) inhibitor, with a Ki of 1.5 nM and an IC50 of 100-300 nM (S. aureus pigment formation)[1]. |
| Target | Ki: 1.5 nM (CrtM).IC50: 100-300 nM (S. aureus pigment formation). |
| In Vivo | BPH-652 treatment (0.5 mg twice per day (days −1, 0, 1, and 2), Intraperitoneal injection) significantly lowers S. aureus bacterial counts in the kidneys of the mice than those of the control group (P < 0.001), with 8 of 13 below the detection threshold, versus only 2 of 14 in the control group; on average, this result corresponds to a 98% decrease in surviving bacteria in the treatment group[1]. Animal Model: |
| Name | BPH-652 |
| CAS | 157124-84-0 |
| Formula | C16H16K3O7PS |
| Molar Mass | 500.63 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Liu CI, et al. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science. 2008 Mar 7;319(5868):1391-4. |
BPH-652
CAS: 157124-84-0 F: C16H16K3O7PS W: 500.63
BPH-652 is a S. aureus dehydrosqualene synthase (CrtM) inhibitor, with a Ki of 1.5 nM and an IC50 of 100-300 nM (S. aure
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.